Recent 8-K filings for IBIO

Each filing is summarized by an LLM — headline, three bullets, event type. The source document on EDGAR is one click away. See methodology.

• May 12, 2026 20:15 UTC earnings item 2.02item 9.01

  iBio Q3: no revenue, cash $74.8M; Phase 1 clearance for IBIO-600; IBIO-610 reduces visceral fat 6.7%

source · IBIO on sec.gov